v3.25.2
NOTES PAYABLE TO RELATED PARTIES
 9 Months Ended
Jun. 30, 2025
Related Party [Member]  
Defined Benefit Plan Disclosure [Line Items]  
NOTES PAYABLE TO RELATED PARTIES

9. NOTES PAYABLE TO RELATED PARTIES

 

Notes payable to related parties consisted of the following:

 

  

June 30, 2025

  

September 30, 2024

 
         
David Koos  $73,303   $1,708 
BST Partners   133,836    - 
Zander Therapeutics, Inc.   59,200    40,000 
           
Total notes payable to related parties   266,339    41,708 
           
Less – current portion   (266,339)   (41,708)
           
Toal notes payable  $-   $- 

 

The terms of notes payable are as follows:

 

  ● David Koos
     
    $73,303 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum.
     
  ● BST Partners
     
    During the quarter ended December 31, 2024 BST Partners lent the Company $46,599 which bears simple interest at a rate of 10% per annum.
     
    During the quarter ended March 31, 2025 BST Partners lent the Company $40,616 which bears simple interest at a rate of 10% per annum.
     
    During the quarter ended June 30, 2025 BST Partners lent the Company $46,621 which bears simple interest at a rate of 10% per annum
     
    BST Partners and the Company are under common control.
     
  ● Zander Therapeutics, Inc.
     
    $15,000 lent to the Company by Zander Therapeutics, Inc. is due and payable on May 3. 2025 and bears simple interest at a rate of 10% per annum.
     
    $25,000 lent to the Company by Zander Therapeutics, Inc. is due and payable on June 5. 2025 and bears simple interest at a rate of 10% per annum.
     
    $10,000 lent to the Company by Zander Therapeutics, Inc. is due and payable on October 4, 2025 and bears simple interest at a rate of 10% per annum.
     
    $4,700 lent to the Company by Zander Therapeutics, Inc. is due and payable on October 15 2025 and bears simple interest at a rate of 10% per annum.
     
    $4,500 lent to the Company by Zander Therapeutics, Inc. is due and payable on October 23 2025 and bears simple interest at a rate of 10% per annum.
     
    Zander Therapeutics, Inc, and the Company are under common control.